Abstract-The reference standards methyl 3-((2,2
Casein kinases (CK) are serine/threonine-specific enzymes and can be divided two subtypes: casein kinase 1 (CK1) and casein kinase 2 (CK2).
1 CK1 contains at least seven isoforms (, , 1, 2, 3,  and ) expressed in eukaryotic organisms, CK1 is involved in various cellular processes including membrane trafficking, circadian rhythm, cell cycle progression, chromosome segregation, apoptosis and cellular differentiation, and deregulation of CK1 activity is linked to several pathological disorders and diseases like cancer, neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and inflammatory disorders. 2, 3 The overexpression of CK1 has been described in the human AD brain, since CK1 leads to an increase in amyloid- (A) peptide production, and also participates in the tau fibrillization reaction pathway through phosphorylation of tau. 4, 5 CK1 has become an interesting therapeutic target for AD where an urgent need for effective treatment exists, because it opens the door for the use of CK1 inhibitors as novel therapeutic approaches for AD. 6 CK1 inhibitors can prevent A formation and reverse tau hyperphosphorylation in AD, and have been used to treat neurodegenerative disorders including AD. 4, 5, 7 Recently a new series of difluoro-dioxolobenzoimidazol-benzamides have been developed as potent CK1 inhibitors with nanomolar inhibitory activity, these compounds exhibited significant inhibitory effects on several tumor cell lines, and their in vitro biological data suggested they can be as therapeutics for AD as well. therapeutic targets. 10 New noninvasive diagnostic imaging modalities for AD are really needed, both to detect and monitor the evolution of this disease, and to evaluate the efficacy of treatments. 11 Advanced biomedical imaging technique positron emission tomography (PET) is one of the most widespread imaging techniques for AD, and significant progress has been made to develop PET agents for two key neuropathological substrates of AD: A plaques and tau neurofibrillary tangles (NFTs). 12, 13 The representative PET A and tau tracers [ 11 16, 17 are listed in Figure 1 . The development of PET imaging probes for in vivo detection of Alzheimer's brains is critical for early and accurate diagnosis and for the successful discovery of AD therapies. 18 The success and limitations of A imaging and tau imaging have spurred efforts worldwide to develop new selective PET tracers for different imaging targets. CK1 has emerged as a new molecular imaging target of AD, 19 but so far no any carbon-11 or fluorine-18 labeled CK1 inhibitors as PET radiotracers for imaging of CK1 were reported. We are interested in the development of new PET AD imaging agents, and a series of enzyme-or receptor-based PET agents have been developed in this laboratory. In our previous work, we have targeted the enzyme glycogen synthase kinase-3 (GSK-3) and developed carbon-11-labeled GSK-3 inhibitors;
20,21 and we have also targeted serotonin (5-hydroxytryptamine) 6 receptor (5-HT 6 R) and developed carbon-11-labeled 5-HT 6 R antagonists, 22 as PET radiotracers for AD imaging (Figure 1 ). In this ongoing study, we first target CK1, which is a novel and attractive molecular target for treatment and PET imaging of AD. 19 Here, we report the design, synthesis and labeling of carbon-11-labeled CK1 inhibitors,
, as new potential PET radiotracers for imaging of AD, for the first time. The basic evaluations of the radiotracers including lipophilicity and stability are presented as well.
The reference standards methyl 3-((2,2-difluoro-5H- [1, 3] 25, 26 in acetonitrile at 80 °C under basic conditions (2 N NaOH). The product was isolated by semi-preparative reverse-phase (RP) high performance liquid chromatography (HPLC) with a C-18 column, and then concentrated by solid-phase extraction (SPE) 27,28 with a disposable C-18 Light Sep-Pak cartridge to produce the corresponding pure radiolabeled compound [ The radiosynthesis was performed in a home-built automated multi-purpose [
11 C]-radiosynthesis module.
29-31 Our radiosynthesis module facilitated the overall design of the reaction, purification and reformulation capabilities in a fashion suitable for adaptation to preparation of human doses. The radiosynthesis includes three stages: 1) labeling reaction; 2) purification; and 3) formulation. 3 I confirmed the result that the labeling yield was improved from 30-35% to 40-45%. The labeling reaction was conducted using a V-vial method. Addition of aqueous NaHCO 3 to quench the radiolabeling reaction and to dilute the radiolabeling mixture prior to the injection onto the semi-preparative HPLC column for purification gave better separation of 33 Overall, it took ~40 min for synthesis, purification and dose formulation.
Our module is designed to allow in-process measurement of [ 11 C]-tracer molar activity (MA, GBq/mol at EOB) using a radiation detector with a UV detector at the outlet of the HPLC-portion of the system. 31 In the HPLC chromatogram, peak analysis of the chromatographic data utilized PeakSimple software (SRI Instruments, Las Vegas, NV). Immediately following elution of the product peak, the chromatographic data are exported to PeakSimple readable files, and the area of the radioactivity peak is converted to GBq -mCi at EOB by comparison to a reference calibration curve previously constructed using the same detector, loop column, mobile phase and flow rate. The mass peak from the UV chromatogram (without decay correction) is similarly compared to a standard curve made at the same UV wavelength, mobile phase and flow rate. Simple division of the total EOB radioactivity peak (in GBq -mCi) by the total mass peak (in nmoles) gives specific activity at EOB in GBq -Ci/mol. For the reported syntheses, product MA was in a range of 370-740 GBq/mol at EOB. The factors that affect the EOB MA significantly to lead to such a wide range have been discussed in our previous works. [34] [35] [36] The general methods to increase SA have been described as well, and the SA of our Chemical purity and radiochemical purity were determined by analytical HPLC. 37 The chemical purity of the precursor and reference standard was >93%. The radiochemical purity of the target tracer was >99% determined by radio-HPLC through -ray (PIN diode) flow detector, and the chemical purity of the target tracer was >90% determined by reversed-phase HPLC through UV flow detector. The octanol-water partition coefficient (commonly expressed as Log P) is an important physical parameter directly correlated with the biological activities of a wide variety of organic compounds. 36,38 Log P provides an assessment of lipophilicity that often correlates with a compound's ability to penetrate the blood brain barrier (BBB). Log P can be determined experimentally by liquid-liquid extraction and by HPLC 38 and can also be theoretically calculated from parameters related to the structure of molecules. We obtained Log P and calculated Log P (CLog P) values of carbon-11-labeled CK1 inhibitors [ 11 26 Melting points were determined on WRR apparatus and were uncorrected. 1 H and 13 C NMR spectra were recorded on a Bruker Avance II 500 MHz NMR Fourier transform spectrometer at 500 and 125 MHz, respectively. Chemical shifts (δ) are reported in parts per million (ppm) relative to an internal standard tetramethylsilane (TMS,  0.0) ( 1 H NMR) and to the solvent signal ( 13 C NMR), and coupling constants (J) are reported in hertz (Hz). Liquid chromatography-mass spectra (LC-MS) analysis was performed on an Agilent system, consisting of an 1100 series HPLC connected to a diode array detector and a 1946D mass spectrometer configured for positive-ion/negative-ion electrospray ionization. The high resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT Classic spectrometer. Chromatographic solvent proportions are indicated as volume: volume ratio. Thin-layer chromatography (TLC) was run using Analtech silica gel GF uniplates (5  10 cm 2 ). Plates were visualized under UV light. Normal phase flash column chromatography was carried out on EM Science silica gel 60 (230-400 mesh) with a forced flow of the indicated solvent system in the proportions described below. All moisture-and air-sensitive reactions were performed under a positive pressure of nitrogen maintained by a direct line from a nitrogen source. Analytical RP HPLC was performed using a Prodigy (Phenomenex) 5 m C-18 column, 4.6  250 mm; mobile phase 60%CH 3 CN/40% H 2 O; flow rate 1.3 mL/min; UV (254 nm) and -ray (PIN diode) flow detectors. Semi-preparative RP HPLC was performed using a Prodigy (Phenomenex) 5 m C-18 column, 10  250 mm; mobile phase 60%CH 3 [1, 3] dioxol-5-amine (2) : Compound 1 (15.6 g, 72.5 mmol) was dissolved in dichloromethane (250 mL). To the resulting mixture, nitronium tetrafluoroborate solution (174 mL, 0.5 M in sulfolane) was added dropwise at 0 °C. After addition, the reaction mixture was allowed to RT and stirred for 24 h. Then the reaction mixture was evaporated to remove dichloromethane, and the resulting mixture was added with water, extracted with EtOAc, washed with water two times, and dried over Na 2 SO 4 . The mixture was filtered, and filtrate was evaporated in vacuo. (f). General procedure for synthesis of compounds 5a-c: Compound 4 (213 mg, 1.0 mmol) and 3-substituted benzoic acid (1.0 mmol) were dissolved in 10 mL of dry N,N-dimethylformamide (DMF), HBTU (417 mg, 1.1 mmol) and DIPEA (258 mg, 2.0 mmol) were added, and the reaction mixture was stirred at RT for 18 h. Then the reaction mixture was concentrated in vacuo. The residue was washed with water, and dried in air to give crude product, which was purified by column chromatography on silica gel with eluent (1:99 to 5:95 MeOH/CH 2 Cl 2 ) to afford a white solid 5. [4',5':4,5] benzo [1,2- [4',5':4,5] benzo [1,2-d] imidazol-6-yl)carbamoyl)benzoic acid (6a): Potassium hydroxide (KOH, 0.5 g, 7.6 mmol) was added into the solution of compound 5a (375 mg, 1.0 mmol) in methanol (20 mL). The reaction mixture was stirred at RT for 15 h. Then the reaction mixture was concentrated in vacuo, and HCl (1 N) was added to adjust pH to 7. The resulting precipitate was filtered, washed with cold water, dried in air to give a white solid 6a (336 mg, 93%), R f = 0.20 (1:9 MeOH/CH 2 Cl 2 ), mp > 310 °C. 1 OEt 2 (0.8 mL) and Me 2 S (1.0 mL) were added to a solution of compound 5b (212 mg, 0.5 mmol) in dichloromethane (20 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 2 h and at RT for 2 h. Then the reaction mixture was evaporated to dryness in vacuo. The residue was suspended in a mixture of aqueous NaHCO 3 , and extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with brine, dried over Na 2 SO 4 , and concentrated. The residue was purified by column chromatography on silica gel with eluent (2:98 MeOH/CH 2 Cl 2 ) to give a white solid 6b (109 mg, 65%), R f = 0.50 (7:93 MeOH/CH 2 Cl 2 ), mp 249-251 °C.
